Abstract
Clinical evaluations of ketotifen are describedin 32 patients with atopic dermatitis, 16 patientswith urticaria (4 with acute urticaria and 12with chronic urticaria), 13 patients with contactdermatitis and 9 patients with astheatoticdermatitis. The number of the whole patientsis 70.One mg of ketotifen capsule is orallyadministered two times daily, after breakfast and before going to bed.
The final global improvement ratio is the following: 78.1% for atopic dermatitis, 75.0% for urticaria, 53.8% for contact dermatitis and 66.7% for astheatotic dermatitis. The incidenceof side effects was 15.7%(11/70). Most ofthe side effects were sleepiness and drowsiness.No abnormal laboratory findings were observedin 6 cases performed.Thus, the global utility rating is the following: 56.3%, 62.5%, 46.2% and 55.6% in order, respectively.
It is concluded that ketotifen is a safe and highly useful drug on the management of atopic dermatitis, urticaria, contact dermatitis and astheatotic dermatitis.
